Biomarkers play a crucial role in the early detection, diagnosis, and management of various diseases. However, the development and validation of reliable biomarkers is a complex and challenging process that requires rigorous evaluation of their analytical and clinical performance. Biomarker validation involves assessing the accuracy, precision, sensitivity, specificity, and reproducibility of the biomarker in a laboratory setting (analytical validation), as well as evaluating its ability to accurately detect or predict the clinical condition of interest in a target population (clinical validation)[1]. In-silico validation, which refers to the computational evaluation of biomarkers using mathematical models, simulations, and data analysis techniques, has become an increasingly important aspect of the biomarker validation process. In-silico validation offers several advantages, including cost-effectiveness, rapid screening of potential biomarkers, hypothesis generation, optimization of assays, and risk assessment. By leveraging computational power and advanced statistical methods, in-silico validation can help identify novel biomarkers, guide the design of subsequent experimental studies, and optimize the performance of biomarker assays. One of the most widely used methods for evaluating the performance of binary classification models, such as those used to predict the presence or absence of a disease based on biomarker levels, is Receiver Operating Characteristic (ROC) curve analysis.[2] ROC curves plot the true positive rate (sensitivity) against the false positive rate (1 - specificity) for different decision thresholds, while the Area Under the ROC Curve (AUC) serves as a summary statistic that represents the overall accuracy of the classification model . ROC and AUC curve analysis provide valuable insights into the performance of biomarkers and help in the selection of optimal cutoff values for clinical decision-making.[3]The objective of this protocol is to provide a comprehensive guide for the in-silico validation of biomarkers using ROC and AUC curve analysis in R, a widely used programming language for statistical computing and graphics. The protocol will cover the necessary steps for data preprocessing, exploratory data analysis, ROC and AUC curve generation, and performance evaluation of biomarkers. By following this protocol, researchers and clinicians can effectively assess the potential of biomarkers for their intended applications and make informed decisions about their clinical utility.